氟达拉滨
氟达拉滨结构式
|
常用名 | 氟达拉滨 | 英文名 | Fludarabine |
|---|---|---|---|---|
| CAS号 | 21679-14-1 | 分子量 | 285.232 | |
| 密度 | 2.2±0.1 g/cm3 | 沸点 | 747.3±70.0 °C at 760 mmHg | |
| 分子式 | C10H12FN5O4 | 熔点 | 265-268ºC | |
| MSDS | 中文版 美版 | 闪点 | 405.8±35.7 °C | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
J. Sci. Ind. Res. 65(10) , 808, (2006) Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the clinic can be tra... |
|
|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared and assayed 33 coumarin derivatives, and the theoretical pr... |
|
|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug Metab. Dispos. 36 , 1385-405, (2008) We present herein a compilation and trend analysis of human i.v. pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data. This data set provides the drug metabolism scientist ... |
|
|
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
Ann. Hematol. 93(8) , 1335-44, (2014) The median age at diagnosis of chronic lymphocytic leukemia (CLL) is 72, but patients enrolled in randomized trials are often a decade younger. Therapy selection and outcomes in the older, comorbid population are less understood. We evaluated treatment patter... |
|
|
Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.
Am. J. Hematol. 89(12) , E239-43, (2014) This phase II trial evaluated efficacy and tolerability of R-CHOP for up to 8 courses in Richter transformation (RT) and up to 6 courses in CLL plus autoimmune cytopenia (AIC) or high-risk (HR) features. HR was defined as fludarabine-refractoriness or early r... |
|
|
Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
Leukemia 28(10) , 1993-2004, (2014) Chronic lymphocytic leukemia (CLL) cells located in proliferation centers are constantly stimulated by accessory cells, which provide them with survival and proliferative signals and mediate chemotherapy resistance. Herein, we designed an experimental strateg... |
|
|
The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.
Br. J. Haematol. 165(1) , 78-88, (2014) Chronic lymphocytic leukaemia (CLL) is the most common haematological malignancy in the U.S. The course of the disease has been shown to be negatively impacted by increased levels of BCL2. Strategies to downregulate BCL2 and shift the balance towards cellular... |
|
|
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients.
Support Care Cancer 22(8) , 2133-40, (2014) Oral mucositis (OM) is a side effect of intensive chemotherapy and radiation and has been reported to affect 75-100% of hematopoietic stem cell transplantation (HSCT) recipients. The purpose of this study was to compare the incidence of OM in patients conditi... |
|
|
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Cancer 121(2) , 234-42, (2015) CPX-351 is a liposome-encapsulated fixed-molar-ratio formulation of cytarabine and daunorubicin that exploits molar ratio-dependent drug-drug synergy to enhance antileukemic efficacy.This phase II study randomized 125 patients 2:1 to CPX-351 or investigators'... |
|
|
Extramedullary relapse following total marrow and lymphoid irradiation in patients undergoing allogeneic hematopoietic cell transplant
Int. J. Radiat. Oncol. Biol. Phys. 89(1) , 75-81, (2014) Purpose Approximately 5-20% of patients can develop extramedullary (EM) relapse after total body irradiation (TBI) containing hematopoietic cell transplant (HCT). While total marrow and lymphoid irradiation (TMLI) provides a more conformally targeted radiothe... |